Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease

K Matsushita, SH Ballew, AYM Wang… - Nature Reviews …, 2022 - nature.com
Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …

Electrochemical biosensors for whole blood analysis: recent progress, challenges, and future perspectives

S Li, H Zhang, M Zhu, Z Kuang, X Li, F Xu… - Chemical …, 2023 - ACS Publications
Whole blood, as one of the most significant biological fluids, provides critical information for
health management and disease monitoring. Over the past 10 years, advances in …

Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease

PM Ridker, M Rane - Circulation research, 2021 - Am Heart Assoc
IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of
physiological functions traditionally associated with host defense, immune cell regulation …

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and …

GC Drosos, D Vedder, E Houben, L Boekel… - Annals of the …, 2022 - ard.bmj.com
Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …

SR Das, BM Everett, KK Birtcher, JM Brown… - Journal of the American …, 2020 - jacc.org
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

The intestinal microbiota fuelling metabolic inflammation

H Tilg, N Zmora, TE Adolph, E Elinav - Nature Reviews Immunology, 2020 - nature.com
Low-grade inflammation is the hallmark of metabolic disorders such as obesity, type 2
diabetes and nonalcoholic fatty liver disease. Emerging evidence indicates that these …

[HTML][HTML] Inflammation and cardiovascular disease: From mechanisms to therapeutics

A Alfaddagh, SS Martin, TM Leucker, ED Michos… - American journal of …, 2020 - Elsevier
Inflammation constitutes a complex, highly conserved cascade of molecular and cellular
events. Inflammation has been labeled as “the fire within,” is highly regulated, and is critical …

Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants

AM Alaa, T Bolton, E Di Angelantonio, JHF Rudd… - PloS one, 2019 - journals.plos.org
Background Identifying people at risk of cardiovascular diseases (CVD) is a cornerstone of
preventative cardiology. Risk prediction models currently recommended by clinical …